ABOUT AVIDITY

Our mission is to profoundly improve people’s lives by delivering a new class of RNA therapeutics – AOCs. Our proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Our advancing and expanding pipeline includes multiple skeletal muscle programs. We are also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution.

Learn More

NASDAQRNA
YearTrailing 12-MonthsCalendar Year 2024Calendar Year 2023Calendar Year 2022Calendar Year 2021Calendar Year 2020Calendar Year 2019Calendar Year 2017Calendar Year 2014
ViewAll FilingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Proxy & Information StatementsOther
FormDescriptionDateFormat
DEF 14AOfficial notification to shareholders of matters to be brought to a vote ("Proxy")April 29, 2022Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in HTML.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in DOC file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in PDF file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in XLS file.
DEFA14AAdditional proxy soliciting materials - definitiveApril 29, 2022Open Additional proxy soliciting materials - definitive in HTML.Open Additional proxy soliciting materials - definitive in DOC file.Open Additional proxy soliciting materials - definitive in PDF file.Open Additional proxy soliciting materials - definitive in XLS file.
MENU